Trial Profile
AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Etrolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms JUNIPER
- Sponsors Roche
- 04 Feb 2024 This study has been completed in Italy.
- 30 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 22 Oct 2023 This study has been completed in Netherland, according to European Clinical Trials Database record.